Mont-Saint-Guibert, Belgium - Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the development of regenerative therapies, announces its participation to the 33rd edition of the annual J.P. Morgan Healthcare Conference which will be held from 12 to 16 January 2015 in San Francisco.
The J.P. Morgan Healthcare conference is the largest and most informative healthcare investment conference. This conference attracts a broad range of US-based analysts and institutional investors.
Cardio3 BioSciences will meet with potential investors and explain to them its on-going development programs and strategic vision for the future.
Patrick Jeanmart, CFO of Cardio3 BioSciences, commented: “2014 was rich in events for our company. We made significant progress in the European Phase III clinical trial of C-Cure® and our strategic development was strengthened by an enlarged collaboration with Mayo Clinic and the acquisition of CorQuest Inc. The J.P. Morgan Healthcare Conference is an excellent opportunity to present Cardio3 BioSciences’ potential and strategic vision to new investors in view of increasing the visibility and the awareness of our Company towards large institutional investors.”
*** END ***
For more information, please contact:
Cardio3 BioSciences
Christian Homsy, CEO
Julie Grade, Corporate Communications Manager www.c3bs.com
Tel. : +32 10 39 41 00
jgrade@c3bs.com
For Europe: Citigate Dewe Rogerson
Chris Gardner Tel : +44 (0) 207 638 9571
Chris.Gardner@citigatedr.co.uk
For the U.S: Rx Communications Group
Eric Goldman Tel: +1 917 322 2563
egoldman@RxIR.com
About Cardio3 BioSciences
Cardio3 BioSciences is a Belgian leading biotechnology company focused on the discovery and development of regenerative and protective therapies for the treatment of unmet medical needs. The company was founded in 2007 and is based in the Walloon region of Belgium. Cardio3 BioSciences leverages research collaborations in the US and in Europe with Mayo Clinic and the Cardiovascular Centre Aalst, Belgium.
The Company’s lead product candidate C-Cure® is an innovative pharmaceutical product that is being developed for heart failure indication. C-Cure® consists of a patient’s own cells that are harvested from the patient’s bone marrow and engineered to become new heart muscle. This process is known as Cardiopoiesis.
Cardio3 BioSciences has also developed C-Cathez®, the most technologically advanced injection catheter with superior efficiency of delivery of bio therapeutic agents into the myocardium.
Cardio3 BioSciences’ shares are listed on Euronext Brussels and Euronext Paris under the ticker symbol CARD.
Help employers find you! Check out all the jobs and post your resume.
